Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

CAMBRIDGE, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announced the ...

Figure 1: The kidney slit diaphragm protein nephrin has multiple YDxV motifs that bind the Nck SH2 domain. Figure 2: Identification of a phosphotyrosine-dependent interaction between nephrin and the ...

The average one-year price target for Nick Scali (ASX:NCK) has been revised to $22.25 / share. This is a decrease of 15.13% from the prior estimate of $26.21 dated February 1, 2026. The price target ...

The development and activation of B cells require signals transduced through the B cell antigen receptor (BCR). The BCR is composed of a membrane-bound immunoglobulin component and the associated ...

We recently compiled a list of the Top 10 ASX Dividend Stocks Heading into 2025. In this article, we are going to take a look at where Nick Scali Limited (NCK.AX) stands against the other ASX dividend ...

NCK Capital has recapitalized Scranton, Pennsylvania-based English Riding Supply, a provider of English-style equestrian equipment and products for both horse and rider. No financial terms were ...

DALLAS–(BUSINESS WIRE)–NCK Capital, a Dallas-based private equity firm specializing in management buyouts, corporate divestitures and recapitalizations of lower, middle-market businesses, announced ...

Nick Scali Ltd. Annual stock financials by MarketWatch. View the latest NCK financial statements, income statements and financial ratios.